Peptide Synthesis: Peptides were synthesized as C-terminal carboxylic acids with uncapped N-termini on Wang resin (100-200 mesh, EMD Millipore). Amino acids were activated with 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU) and N-hydroxybenzotriazole (HOBt) in the presence of N,N-diisopropylethylamine (DIEA), except for the C-terminal residue. C-terminal residues were coupled onto resin using 1-(mesitylene-2-sulfonyl)-3-nitro-1H-1,2,4-triazole (MSNT) as a coupling agent as described previously.
1 Main chain peptide amino groups were Fmoc-protected. The growing peptide chain was deprotected using 20% piperidine in DMF. Peptide 4a was purchased from GenScript (>95% purity). Protected β 3 -homoamino acids were purchased from PepTech and ChemImpex. After synthesis, the peptides were cleaved from the resin and side chains were deprotected using reagent K (82.5% TFA, 5% phenol, 5% H 2 O, 5% thioanisole, 2.5% ethanedithiol) for two hours. The reagent K solution was dripped into cold diethyl ether to precipitate the deprotected peptide. Peptides were purified via reverse-phase HPLC on a prep-C18 column. Following collection and lyophilization of HPLC fractions containing the desired product, peptides 7, 8, and 9a-d were redissolved and relyophilized twice in 50 mM HCl to enable exchange of trifluoroacetate counterions for chloride counterions to avoid potential toxicity issues resulting from exposure of animals to high concentrations of trifluoroacetate. Peptide purity was assessed by analytical reserve phase-HPLC (solvent A: 0.1% TFA in water, solvent B: 0.1% TFA in acetonitrile, C18 analytical column (4.6 X 250 mm), flow rate 1 mL/min, gradient 10-60% B solvent over 50 minutes) by quantifying the area under the peak corresponding to the desired product. HPLC purity checks were run before and after counter anion exchange. Masses were measured by MALDI-TOF-MS. See SI Figure S5 for peptide sequences and SI Table 1 for analytical HPLC retention times, purity data and a list of observed masses from MALDI-TOF-MS (average [M+H] + , m/z). See SI Figure S6 for HPLC chromatograms and MALDI-TOF mass spectra. Peptides 4a, 4b, 5, 6a, 6b, 6d, and ent-4a show major signals in MALDI at a mass corresponding to the sodium (M+H+22) adduct. For peptides 7, 8 and 9a-d chromatograms from HPLC purity checks run before counter anion exchange are displayed first, followed by chromatograms from HPLC purity checks run after counter ion exchange. Some mass spectra for peptides 7, 8 and 9a-d show strong signals corresponding to sodium (M+H+22) and potassium (M+H+38) adducts.
Selection of Peptide Sequence:
Protected forms of many β 3 amino acids are commercially available, but not protected β 3 -homocysteine. Since the native sequence of the 9-mer LCMV glycoprotein epitope (GP33, residues 33-41) used in these studies contains a cysteine residue at the C-terminal residue (KAVYNFATC), we based our studies of GP33 recognition on a variant containing a Cys→Met substitution at the C-terminal position (KAVYNFATM, peptide 7). Previous studies have shown that this Cys→Met variant binds to the relevant MHC-1 2 and that the peptide-MHC-1 complex is recognized by cognate T-cell receptor (TCR) 3 similarly to the natural GP-33 9-mer. SI Figure S1 . Human Bim BH3 derived α-peptide (1) and α/β analogues (2, 3a,b,d), and GP33 α-peptide (7) and α/β analogues (8, 9a-d) do not adopt significant secondary structure in aqueous solution. Circular dichroism spectra of the indicated peptides were obtained at 20° C with 50 µM peptide in 10 mM sodium phosphate, pH 7.0 buffer. (a) CD specta of human Bim BH3 and analogues. Peptide 3c was not sufficiently soluble in sodium phosphate buffer to collect data. (b) CD specta of GP33 and analogues.
SI Figure S2 . Neither unconjugated α-peptide 4a nor α/β-peptide 5 is able to induce production of peptide specific IgY antibodies when injected into chickens with adjuvant. Data points represent mean ± SD, with each condition run in duplicate. In all panels, ovalbumin-conjugated peptides were immobilized using a 1:100 dilution of the solution produced from the ovalbumin conjugation reaction. (a) Indirect ELISA of IgY antibodies from chickens injected with unconjugated α-peptide 4a (anti-4a). The x-axis represents the dilution of egg yolk used for each condition. "FCA" data points are generated using egg yolks from chickens injected only with Freund's complete adjuvant (FCA), which serve as negative controls. (b) Indirect ELISA analysis based on α/β-peptide 5; details as in part (a). Figure S3 . Antibody responses induced following inoculation with carrier protein-conjugated α-peptide 4b or α/β-peptides 5 or 6b are reproduced when injecting multiple chickens (n = 4). Association of antibody with immobilized peptide was evaluated only between antibodies and the carrier protein conjugated peptide injected to stimulate production of that antibody. In all panels, ovalbumin-conjugated peptides were immobilized using a 1:100 dilution of the solution produced from the ovalbumin conjugation reaction. (a) Indirect ELISA analysis of IgY antibodies induced from injection of carrier protein-conjugated 4b, 5 and 6b. The x-axis represents the dilution of egg yolk used. "FCA" data points are generated using egg yolks from chickens injected only with Freund's complete adjuvant (FCA), which serve as negative controls. (b) Competitive ELISA analysis of peptides in solution (peptide competitor) inhibiting the binding of egg yolk derived antibodies to immobilized peptides 4b, 5 or 6b. The number in parentheses following the number identifying the peptide hapten indicates which replicate chicken is evaluated in that row. The x-axis represents the concentration of free peptide incubated with egg yolk preparations before adding this solution to wells containing immobilized peptides. IC 50 values were estimated manually as the concentration of peptide needed to eliminate approximately 50% of the signal (absorption at 405 nm) resulting from complex formation between IgY antibodies and immobilized peptide. All competition ELISA curves may be found in Figure S4 . Figure S4 . Antibody responses induced by injection of sPLA2 fragment peptides are generally specific to the immunizing peptide. Competitive ELISA analysis of peptides in solution inhibiting the binding of egg yolk-derived antibodies to ovalbumin-conjugated, immobilized sPLA2 peptides. Ovalbumin-conjugated peptides were immobilized using a 1:100 dilution of the solution produced from ovalbumin conjugation reaction as described in the methods section. The first listed number identifies the peptide injected and the following number in parentheses indicates which replicate chicken is evaluated in that graph. The x-axis represents the concentration of free peptide incubated with egg yolk preparations before adding this solution to wells containing immobilized peptides. Figure S5 . Neither Bim BH3-derived α-peptide 1 nor α/β-peptide 2 stimulates expansion of peptide-specific CD8 + T-cells in vivo. Flow cytometry analysis (plots not shown) of splenocytes derived from mice injected with α-peptide 1 (a) or α/β-peptide 2 (b) show no increase in the frequency of peptide-responsive CD8+ splenocytes compared to no-peptide controls. Peptides were injected into 4 mice each, and splenocytes from these 4 mice were pooled for experiments. Data represent mean ± sd from 4 replicate experiments. "Medium" represents the frequency of IFNγ producing CD8 + lymphocytes observed with no peptide stimulation for that population of splenocytes. 
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